<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Ruby Cy Lin</style></author><author><style face="normal" font="default" size="100%">Jessica C Sacher</style></author><author><style face="normal" font="default" size="100%">Pieter-Jan Ceyssens</style></author><author><style face="normal" font="default" size="100%">Jan Zheng</style></author><author><style face="normal" font="default" size="100%">Ali Khalid</style></author><author><style face="normal" font="default" size="100%">Jonathan R Iredell</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">Australian Phage Biobanking Network</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Phage Biobank: Present Challenges and Future Perspectives.</style></title><secondary-title><style face="normal" font="default" size="100%">Curr Opin Biotechnol</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Australia</style></keyword><keyword><style  face="normal" font="default" size="100%">Bacteriophages</style></keyword><keyword><style  face="normal" font="default" size="100%">Biological Specimen Banks</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">phage therapy</style></keyword><keyword><style  face="normal" font="default" size="100%">Reproducibility of Results</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2021 04</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">68</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;After a century of use in human infection, the preparation and administration of therapeutic bacteriophages (phages) still relies on ad hoc partnerships of researchers, biotech companies, clinicians and regulators. There is a clear need to improve the reproducibility, safety and speed of the provision of suitable phages. Here we discuss the specific characteristics and challenges of a sustainable phage biobank and, as we build a national consortium aimed at delivering phage therapeutics, suggest a roadmap toward national biobanking and phage therapy initiatives using the Australian context as a model.&lt;/p&gt;
</style></abstract></record></records></xml>